Skip to Content

Zontivity (vorapaxar) Disease Interactions

There are 3 disease interactions with Zontivity (vorapaxar):

Major

Vorapaxar (Includes Zontivity) ↔ Bleeding

Severe Potential Hazard, High plausibility

Applies to: Peptic Ulcer, Intracranial Hemorrhage, Bleeding Associated with Coagulation Defect

Vorapaxar increases the risk of bleeding and it is contraindicated in patients with active pathological bleeding such as intracranial hemorrhage or peptic ulcer. In other patients, consider the underlying risk of bleeding before initiating therapy. General risk factors include older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and use of certain concomitant medications. The use of warfarin and other anticoagulants should be avoided. Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or any other surgical procedure.

Major

Vorapaxar (Includes Zontivity) ↔ History Of Stroke

Severe Potential Hazard, Moderate plausibility

Applies to: History - Cerebrovascular Disease, Intracranial Hemorrhage, Cerebral Thrombosis/Embolism

Vorapaxar is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial bleeding. The risk of intracranial bleeding is higher in these patients.

Major

Vorapaxar (Includes Zontivity) ↔ Liver Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

No dose adjustment is required in patients with renal dysfunction or mild to moderate hepatic impairment. Vorapaxar is not recommended in patients with severe hepatic impairment due to bleeding risk.

Zontivity (vorapaxar) drug Interactions

There are 219 drug interactions with Zontivity (vorapaxar)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide